Chris Rhodes Email & Phone Number

San Diego, CA, US

Baywind Bioventures is a business investment and advisory firm with emphasis in biopharmaceuticals, the food and beverage industry, and higher education. Leadership has 50 years of experience in corporate product development in Fortune 100 consumer products and biotechnology companies, substantial startup experience, and academic administration.

CASS is developing delivery enabled pharmaceutical products. Founded by a team of experienced executives in the biopharmaceutical and drug delivery technology space.

Head of product development, responsible for translating delivery technology from late stage research through clinical proof of concept.First product is glucose-responsive insulin designed to improve glycemic control in patients using insulin. Responsible for technology R&D, intellectual property, scale-up, manufacturing, product development and business.

Advisory Council, Keck Graduate Institute (2016-present)President, Boulder Peptide Symposium (2016-present)Chair of Scientific Advisory Board and Board of Trustees, Boulder Peptide Symposium (2011-2016)Domain Expert, CONNECT Springboard Program for entrepreneurs (2011-present)Advisory Board, UCSD Biomedical Engineering (2009-present)Industrial Advisory.

Drug Delivery Experts, a specialty CDMO with small scale parenteral fill finish capabilities was sold to Pace Life Sciences in July 2021. Built the company from the ground up and sold as a profitable business.

• Pharmaceutical product development consulting
• Interim leadership and management
• Direct technical R&D support
• Portfolio strategy and life cycle plans
• Technology evaluation and due diligence Clients include start-up to fully integrated pharma to venture firms with interest in biopharmaceutical, drug delivery, device, specialty pharmaceutical products and.

Head of product development for ocular company advancing novel technologies from research to clinical concept for small molecules and biologics, responsible for technology R&D, intellectual property, scale-up, manufacturing, project and business development.- Key technical lead for company supporting business development and financing discussions- Set up.

San Diego, CA, US

• Amylin Pharmaceuticals is a mid-sized biotechnology company engaged in the discovery, development, and commercialization of peptides and proteins for diabetes and obesity, has two commercial products (Symlin and.
• Head of pre-formulation, drug delivery, bio-analytical chemistry responsible for peptide and protein development from discovery through commercial (35 staff, $10-15M annual budget)
• Head of the drug delivery program responsible for strategy, technology identification, feasibility studies, development candidate selection, clinical testing ($20M annual budget)
• Delivery strategy leader for corporate partnership (Eli Lilly, Takeda, Biocon, Psylin) portfolios in diabetes, obesity, depression consistent with platform technology vision
• Led the Amylin-Lilly Alliance drug delivery program through preclinical and clinical testing of nasal, pulmonary, transdermal, and oral technologies for exenatide ($20M annual budget)
• Negotiated licenses for technologies including upfront fees up to $8M, clinical milestone fees totaling up to $29M, escalating royalties for single and multiple products in a platform

US

• Guilford Pharmaceuticals (later MGI and then Eisai) was a small pharmaceutical company engaged in CNS drug discovery and development with a commercial product (Gliadel wafer) for brain cancer, and a polymer microsphere.
• Head of pre-formulation, formulation development, analytical chemistry responsible for small molecule and polymer delivery system development (45 staff, $10M annual budget)
• Responsible for lead molecule selection, transition to clinical development, and development of formulations and clinical supply for development
• Led cross-functional clinical development teams for new therapeutics in peripheral diabetic neuropathy and procedural sedation (30 staff, $5-10M annual budget)
• Developed commercial launch configuration for intravenous injection (propofol pro-drug)
• Developed immediate, controlled release, and chewable tablet prototypes for commercial formulation for a high dose drug for Parkinson’s disease

Danbury, CT, US

• Pharmaceutical Discovery Corporation (later Mannkind) was a start-up engaged in discovery and development of fluorescent diagnostic systems, an Alzheimer's drug, and the Technosphere inhalation delivery system which is.
• Head of formulation, chemistry, biology, pharmacokinetics (20 staff, $5M annual budget)
• Responsible for design, synthesis, and development of a propriety drug delivery technology
• Team leader for partnership and collaborative drug delivery contract work, the primary revenue generator for the company (contracts up to $1M)
• Developed inhalation dry powder formulations of insulin, calcitonin, parathyroid hormone
• Developed protein formulation for subcutaneous infusion and small molecule suspension formulation for intravenous injection

Post Doc, Chemistry

Ph.D., Chemistry

B.S., Chemistry